Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanced melanoma. However, approaches to non-invasively visualize the persistence of transferred T cells are lacking. We examined whether positron emission tomography (PET) can monitor the distribution of self-antigen-specific T cells engineered to express an herpes simplex virus 1 thymidine kinase (sr39tk) PET reporter gene. Micro-PET imaging using the sr39tk-specific substrate 9-[4-
Introduction
Recent advances in tumor immunology have led to the development of novel immunotherapies for cancer. While clinical trials using cancer vaccines have yielded low objective response rates (1) , recent approaches based on adoptive cell transfer immunotherapy have shown significantly higher efficacy. Rosenberg and colleagues have demonstrated partial and complete responses in ;50% of patients with metastatic melanoma treated with adoptive transfer (AT) of ex vivo expanded autologous tumor-infiltrating lymphocytes and a lymphodepleting host conditioning regime (2, 3) . However, it remains unclear why some patients do not respond to treatment. Potential explanations include low TCR affinity for tumor antigens, sub-optimal in vivo expansion, failure of adoptively transferred T cells to gain access to secondary lymphoid organs or lack of tumor targeting. Currently, conventional immune monitoring approaches to address some of these potential rate-limiting steps involve quantitative and functional analyses of T cells isolated from peripheral blood or tumor biopsies (4) . While these assays provide critical data, their main limitation stems from the inability to accurately reflect the dynamic changes in the distribution and numbers of T cells in lymphoid organs and at tumor sites. In particular, the potential for sampling error is increased in patients with metastatic disease and/or tumor lesions that are poorly accessible to surgical or fine needle biopsies. There is a need for non-invasive whole-body immune monitoring assays that correlate and/or predict the clinical endpoints of adoptive immunotherapy trials.
The advent of molecular imaging techniques could overcome these limitations by enabling serial and non-invasive visualization of adoptively transferred T cells throughout the body. Various techniques based on optical (5), nuclear (6) or magnetic resonance (7) imaging modalities have been used to visualize T cells in vivo. We and others have focused on developing positron emission tomography (PET) imaging approaches for immune monitoring [reviewed in (8) ]. PET allows three-dimensional (3D) and quantitative measurements of the tissue accumulation of probes labeled with positron emitting radioisotopes. The sensitivity of PET is in the low nanomolar range and, unlike optical imaging modalities, measurements of probe accumulation are minimally impaired by tissue absorption and scattering. Importantly, PET studies in animal models are fully translatable to the clinic. Clinical PET scanners have similar sensitivities to micro-PET instruments used to image rodents. Furthermore, while their spatial resolution is a log order less than that of pre-clinical imaging systems, the physical size of the imaged human subject is also several orders of magnitude larger thereby reducing the resolution requirements.
A common thread among previous studies on PET imaging of anti-tumor T-cell responses relates to the strong immunogenicity of cancer antigens targeted in these studies (9) (10) (11) (12) (13) . Using PET reporter gene imaging, Koehne et al. (9) visualized the accumulation of EBV-specific T cells in EBV-positive tumors expressing the correct HLA-restricting element but not in EBV-negative or HLA-mismatched tumors. In a series of studies, our group has demonstrated the capability of PET reporter gene imaging to monitor primary and secondary anti-tumor T-cell responses to xenoantigens encoded by sarcomainducing oncoretroviruses (10, 11, 13) . Su et al. (14) established a correlation between the numbers of anti-tumor T cells specific for a model antigen and the retention of the reporter probe measured by PET. Similarly, another recent study correlated PET signal intensities over time with quantitation of transduced EBV-specific T cells detected in the tumor (15) . While these studies have validated the feasibility of using PET reporter gene imaging for monitoring anti-tumor immunity, T-cell responses to strong foreign or model antigens are quantitatively different than those against non-mutated self-antigens more commonly expressed by human cancers of non-viral etiologies. In general, such autoreactive immune responses are of much lower magnitude than responses to foreign antigens and are mediated by low affinity T cells that have evaded central and peripheral tolerance induction mechanisms (16, 17) . These differences raise the question whether PET reporter gene imaging has the required sensitivity to allow monitoring of T-cell responses against non-mutated self-antigens that are frequently targeted by adoptive immunotherapies in melanoma and other types of cancer (18) .
In the current study, we used a model of adoptive immunotherapy against melanoma which reproduces several key aspects of the adoptive immunotherapy clinical trials performed at the National Cancer Institute (18, 19) . To enable detection of T cells following AT, we transduced these cells with the PET reporter gene sr39tk, an optimized variant of the herpes simplex virus 1 (HSV1) thymidine kinase (20) . Cells engineered to express sr39tk can be visualized by micro-PET using the high-affinity substrate (9- (21) . The findings of the current study were 3-fold: (i) the quantitation of T-cell expansion in lymphoid organs as measured by [ 18 F]FHBG micro-PET scans at early time points following AT was predictive of the efficacy of adoptive immunotherapy; (ii) sr39tk-expressing melanoma-specific T cells can be serially imaged by [ 18 F]FHBG micro-PET and (iii) the sensitivity of [ 18 F]FHBG PET reporter gene imaging enables detection of very low numbers of sr39tk+ T cells present in the spleen and lymph nodes (LNs) of treated mice. These data suggest that the ability of non-invasive PET imaging to measure the reconstitution, expansion and persistence of adoptively transferred T cells into patients may have significant clinical utility for providing early predictions of treatment efficacy. PET reporter imaging approaches can be incorporated into the design of clinical trials to evaluate novel adoptive T-cell-based immunotherapies against melanoma and other types of cancer.
Materials and methods

Cell lines and animals
B16-F10 (B16), a murine melanoma cell line, was obtained from the American Type Culture Collection (Rockville, MD, USA). Stably transfected cells were cultured in DMEM (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% FCS (Gemini, Calabasas, CA, USA). C57BL/6 and pmel-1 mice were bred and maintained according to the guidelines of the Department of Laboratory Animal Medicine (DLAM) at the University of California, Los Angeles. All animal studies were carried out by using protocols that had been approved by DLAM.
In vitro activation of pmel-1 T cells and retroviral transduction
The retroviral vector of murine stem cell virus (pMSCV) (22) containing a 5# long terminal repeat-driven truncated version of the sr39tk fused with super enhanced yellow fluorescent protein (seYFP) was used to generate high-titer helper-free retrovirus stocks prepared by transient co-transfection of 293T cells. LNs were harvested from pmel-1 mice and cultured with IL-2 (100 U ml
À1
) and gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide (1 lg ml À1 ). At 48 and 72 h post-activation, the cells were spinfection with the MSCV-sr39tk-seYFP retrovirus (;10 multiplicity of infection) and 2 lg ml À1 of lipofectamine (1800 r.p.m., 120 min, 32°C, Beckman CS-6R centrifuge). Upon in vitro stimulation, pmel-1 CD8 + T cells developed an early effector phenotype defined by activation markers such as up-regulation of CD25 and CD69 and of lymphoid-homing molecules (partial down-regulation of CD62L and expression of CCR7) (23) . Approximately >95% of all of the adoptively transferred cells were CD8 + /Vb13+ T cells (data not shown). seYFP was used to monitor transduction efficiency before AT, which was routinely >50-70%.
AT, vaccination and tumor treatment
Six-to 12-week old female C57BL/6 were injected subcutaneously (s.c.) with 1 3 10 5 B16 melanoma cells on day À8. On day À1, lymphopenia was induced by sub-lethal irradiation (500 cGy) of tumor-bearing mice. On the next day (day 0), mice with similarly sized tumors were randomized into groups: (i) no adoptive cell transfer therapy (ATX), (ii) ATX of 2-5 3 10 6 transduced pmel-1 cells and (iii) ATX of 2-5 3 10 6 transduced pmel-1 cells plus gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide-pulsed dendritic cell (DC) and human IL-2 (50 000 IU intra-peritoneally for 3 days after each DC administration). Caliper measurements of the tumors were recorded, and the tumor volume was calculated with the formula: 4/3p 3 width radius 3 length radius 3 height radius.
DC preparation
DCs were differentiated from bone marrow progenitor cells obtained from C57BL/6 mice by in vitro culture in murine granulocyte macrophage colony-stimulating factor (100 ng ml À1 ; Amgen, Thousand Oaks, CA, USA) and murine IL-4 (500 U ml
À1
; R&D Systems, Minneapolis, MN, USA) as described by Inaba (24) , with minor modifications (25) . DCs were harvested as loosely adherent cells, washed twice in PBS (Mediatech, Herndon, VA, USA) and pulsed with gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] peptide at a concentration of 10 lM in serum-free media for 90 min at room temperature. Each mouse received ;10 6 pulsed DCs given s.c. at 4 sites on the back.
Micro-PET/computed tomography imaging
Animals were anesthetized, injected intravenously (i.v.) with [ 18 F]FHBG and scanned using a FOCUS 220 micro-PET scanner (Siemens, Knoxville, TN, USA) as described previously (20) . Images were reconstructed from the scanner data by using an iterative maximum a posteriori algorithm (26) . In the same session, mice were injected i.v. with Fenestra LC contrast agent (Advanced Research Technologies, Quebec, Canada) and computed tomography (CT) images were acquired on a micro-CAT II instrument (Siemens). Using Amide, quantification was performed by drawing regions of interest (ROIs) to determine the amount of [
18 F]FHBG (microcurie) present. Animals were euthanized on approximately day 3 post-AT, immediately following micro-PET imaging. Spleen, LNs and tumors were harvested, scanned by micro-PET ex vivo and then counted in a gamma counter (Perkin Elmer).
Isolation and analysis of adoptively transferred cells
Single-cell suspensions were prepared by dissociating LNs through a mesh cell strainer in DMEM + 5% fetal bovine serum media. Single-cell suspensions of spleens were prepared in media containing 1.5 mg type IV DNase (Roche, Mannheim, Germany). RBCs were lysed with 13 PharmLyse buffer (PharMingen, San Diego, CA, USA). Tumors were dissected, minced and incubated at 37°C for 1-2 h in media containing 1.5 mg type IV DNase, 15 mg type IV collagenase (Gibco) and 37.5 U type V hyaluronidase (Sigma, St Louis, MO, USA). Ficoll gradients were performed on single-cell suspensions. Cells were mixed with a known number of Accucount Blank Particles (Spherotech, Libertyville, IL, USA), stained with 7AAD (Becton Dickinson) and analyzed on a FACSCanto instrument (Becton Dickinson). Total cell density and viability were calculated from the ratio of 7AAD to beads using the Diva software (BD). Cells were also stained with Vb13-FITC (BD) and CD8-PE-Cy7 (BD) to determine the percentage of Vb13+ sr39tk-seYFP+ CD8 T cells. Linear regressions of the total number of Vb13+ sr39tk+ cells versus the amount of [
18 F]FHBG (microcurie) present in tissues of interest were analyzed using the PRISM software (version 4.02; GraphPad, San Diego, CA, USA).
Autoradiography and histology
Mice were anesthetized with 2% isoflurane and injected i.v. with 500 lCi of [
18 F]FHBG. After 1 h, mice were sacrificed and tumors were harvested and embedded in the optimum cutting temperature compound (Sakura Finetek, Torrance, CA, USA). Frozen sections (4 lm) were sliced using a microtome (Leica) and exposed on BAS-TR2025 imaging screens overnight (FujiFilm Life Science, Stamford, CT, USA). The screens were developed a BAS-5000 phosphor imager (FujiFilm Life Science). Hematoxylin and eosin staining was performed on the same frozen sections.
Results
[
18 F]FHBG PET/CT imaging enables visualization of melanoma-specific CD8 + T cells in the spleen and LNs of tumor-bearing mice Pmel-1 TCR transgenic mice were used to determine whether T-cell responses specific for tumor-expressed selfantigens can be visualized by PET reporter gene imaging. CD8
+ T cells from these mice express a TCR specific for an antigenic epitope derived from the unmutated melanoma/ melanocyte-associated antigen, gp100. Tumor regression requires a combined immunotherapy protocol consisting of AT of T cells, lymphodepletion (X-ray therapy, XRT), peptidepulsed DC vaccination and high-dose systemic IL-2 (full regime, Fig. 1A ) (19, 23, 27, 28) . Omission of any of these components compromises treatment efficacy and results in tumor progression. In a series of four independent studies, we confirmed the requirement for gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] /DC and IL-2 to induce regression of established B16 melanoma following AT of pmel-1 cells (Fig. 1B) .
Ex vivo-stimulated pmel-1 T cells were retrovirally transduced with the PET reporter gene sr39tk to enable visualization and tracking with PET imaging (Fig. 1A) . [ 18 F]FHBG micro-PET images were merged with high spatial resolution CT images to provide anatomical information. High-definition whole-body mouse images were generated by algebraic reconstruction of collected 3D emission data (26) . 3D PET images are displayed as a measure of percent injected dose per gram of tissue in a false color scale, with red indicating the highest amount of radioactivity present at that location. In mice, [ 18 F]FHBG also accumulates non-specifically in the gall bladder, small and large intestine as well as in the kidney and bladder due to clearance of the non-phosphorylated probe by hepatobiliary and renal routes. To overcome the background in the lower abdomen, a contrast agent (Fenestra LC) was used for precise identification of the spleen using micro-CT imaging.
Mice were imaged on day 3 post-transfer. Top panels of Fig. 2 show representative 3D whole-body [ 18 F]FHBG micro-PET/CT scans of mice receiving the full regime (XRT + AT + IL-2 + DC) or incomplete therapy (XRT + AT). We focused on three anatomical locations: spleen, LNs and the tumor. [ 18 F]FHBG signals corresponding to the spleen were observed in mice receiving the full regime, the only therapy leading to objective tumor responses (Fig. 1A) . The [ 18 F]FHBG spleen signal was reproducibly observed in all scanned animals from the full regime group (N = 37, eight independent experiments). Eight-six percentage of mice receiving the full regime also showed [ 18 F]FHBG accumulation in peripheral LNs (PLNs), including the axillary, brachial and cervical nodes ( Fig. 2A, bottom panel) . In contrast, none of the mice receiving AT and lymphodepletion without vaccination and cytokine treatment (XRT + AT group, N = 30, in seven independent experiments) showed detectable [ 18 F]FHBG accumulation in secondary lymphoid organs (Fig. 2B, bottom panel) . Therefore, at this early time point (72 h post-transfer), [ 18 F]FHBG micro-PET/CT detected T-cell homing and expansion at the spleen and LNs. Quantitation of [ 18 F]FHBG retention in secondary lymphoid organs allowed us to non-invasively differentiate between mice with and without combined immunotherapy.
Non-specific accumulation of [ 18 F]FHBG at the tumor site
As shown in the bottom panels of Fig. 2 , both groups of mice receiving full regime or incomplete therapy showed detectable accumulation of [ 18 F]FHBG in the B16 melanoma lesions. We reasoned that such signals could be explained by two potential mechanisms. First, adoptively transferred sr39tk+ T cells could traffic to the tumor independently of the DC vaccination and IL-2 treatment. Second, the signal at the tumor site could reflect sr39tk+ T-cell-independent trapping of the probe. When tumors of mice receiving AT of sr39tk+ T cells with and without full regime were dissociated, the number of Vb13+ sr39tk+ cells present did not correlate with the [
18 F]FHBG signal measured ( Fig. 3A and B) . To further distinguish between these two possibilities, B16 tumor-bearing mice that received only whole-body irradiation without AT of sr39tk+ T cells (the XRT group) were imaged. As shown in Fig. 2(C Figure 1A and Figure 1D -F, available at International Immunology Online). Non-specific probe trapping could also be explained by the particular architecture of the B16 tumors. These tumors are highly vascularized and show areas of blood pooling which could decrease probe clearance, as shown by histology and autoradiography (Fig. 3E) . Given these observations, in subsequent experiments, we focused on imaging T cells in secondary lymphoid organs which, in contrast to B16 lesions, do not show non-specific retention of [ 18 F]FHBG. Fig. 4(A) , these mice received three doses of gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] /DC vaccination and systemic IL-2 treatment at 6-day intervals (red arrows, Fig. 4B ) (27) . The micro-PET imaging schedule was selected based on previous studies showing that maximal expansion of adoptively transferred pmel-1 T cells in recipient mice can be detected on days 5-7 post-AT in the spleen, tumor draining LNs (DLNs) and at the tumor site (29) . Later time points were included to determine if repeated DC vaccination and IL-2 treatment could induce micro-PET measurable changes in the distribution and/or numbers of adoptively transferred T cells.
Following the rapid expansion of adoptively transferred cells visualized in the spleen on day 3 post-transfer ( Fig. 2A) 18 F]FHBG retention could reflect the rapid initial expansion of adoptively transferred cells due to homeostatic proliferation in a lymphodepleted environment with an exogenous supply of IL-2 and/or the antigen-dependent T-cell proliferation by gp100-pulsed DCs, followed by the contraction phase at later time points (29) . Alternatively, the loss of the 
Quantification of [ 18 F]FHBG PET signals in secondary lymphoid organs
The experimental strategy shown in Fig. 5(A) was used to determine whether the numbers of adoptively transferred sr39tk+ T cells in the spleen and LNs of treated mice correlate with [ 18 F]FHBG accumulation measured in vivo by micro-PET. Immediately following whole-body micro-PET scans, mice receiving the full regime or XRT + AT were sacrificed and isolated organs were imaged by micro-PET ex vivo. As shown in Fig. 5(B) , ex vivo scans confirmed the identity of the lymphoid organs imaged in vivo. Gamma counter measurements were performed to more precisely estimate the [ 18 F]FHBG retention in isolated organs. We observed increased amounts of [ 18 F]FHBG in the spleens of mice receiving the full regime (1.9 6 0.4 lCi) versus XRT + AT-treated mice (0.05 6 0.01 lCi, P < 0.05). The same pattern was detected in LNs isolated from these mice (23.0 6 4.6 nCi for the full regime-treated mice versus 3.3 6 0.9 nCi for XRT + AT-treated mice, P < 0.05). The in vivo micro-PET ROI-based measurements of [ 18 F]FHBG retention showed an excellent correlation with radioactivity measurements of ex vivo lymphoid organs acquired by the gamma counter, thus confirming our method to quantify the [ 18 F]FHBG micro-PET signals (data not shown). To determine whether the numbers of Vb13+ sr39tk+ pmel-1 T cells present in secondary lymphoid organs correlate with the amount of [
18 F]FHBG detected at these sites, we performed flow cytometric analyses on singlecell suspensions isolated from spleen and LNs. We observed higher percentages and total numbers of sr39tk+ cells expressing the Vb13+ pmel-1 TCR in the spleens and LNs of mice treated with the full regime compared with the XRT + AT group (Fig. 5C) . ROI-based quantitation of in vivo [
18 F]FHBG accumulation in the spleen and LNs showed a good correlation with numbers of Vb13+ sr39tk+ cells present ( Fig. 5D and E (Fig. 5E ).
Discussion
Advantages and limitations of PET reporter gene imaging of adoptive immunotherapy in cancer
Adoptive immunotherapies aim to overcome immunological tolerance to cancer by transferring autologous tumorspecific T cells expanded ex vivo. Although promising 'proof-of-concept' studies have been reported in recent years, identification of suitable biomarkers of protective T-cell anti-tumor immune responses remains a major challenge. We describe a PET reporter gene imaging approach which allows visualization of melanoma-specific T cells following AT in tumor-bearing mice. The advantages of this approach are as follows: (i) the ability to sequentially monitor adoptive immunotherapy for extended periods of time; (ii) high sensitivity, as demonstrated by the capability to detect rare populations of T cells at various anatomical locations and (iii) the safety, pharmacokinetics and dosimetry of [ 18 F]FHBG have been studied in rats, rabbits and normal human volunteers, and the US Food and Drug Administration has approved its use as an investigational new drug in clinical trials (30) (31) (32) . These studies simplify the regulatory steps required to translate this imaging approach from mice to cancer patients. (33, 34) . Another advantage of this approach is that HSV1-tk was originally designed for suicide gene therapy of cancer. Thus, HSV1-tk would be delivered to cancer cells and then administration of a pharmacological dose of gancyclovir would cause death of these cells. This built-in safety feature should prevent possible adverse effects, including malignant transformation as a consequence of random insertion of viral constructs and life-threatening autoimmunity. The combination of [ Several clinical trials showed that HSV1-tk gene-modified lymphocytes for allogeneic hematopoietic stem cell transplants in leukemic patients could be detected in circulation, bone marrow and peripheral tissues for >12 months, while maintaining their anti-tumor activity (35) (36) (37) (38) . However, using quantitative PCR assays, these studies have also revealed a significant incidence (in ;23% of patients) of immune responses against HSV1-tk, leading to a decrease in the number of circulating cells (35, 39) . In contrast, it is possible that the myeloablative chemotherapeutic regime will significantly reduce the possibility of host immune responses against sr39tk+ adoptively transferred T cells. Other options to approach the immunogenicity problem are to (i) use less immunogenic HSV1-sr39tk variants (40) Figure 3 , available at International Immunology Online). Nonetheless, our findings indicate the need to further optimize existing PET reporter gene approaches by (i) development of PET reporter genes that are less immunogenic and potentially more sensitive than sr39tk and (ii) radiochemical synthesis and testing of novel sr39tk substrates with lower non-specific accumulation than FHBG.
The lower limit of detection of PET reporter gene imaging
The approach described here was sensitive to variations in the strength of the immunotherapeutic regime and allowed quantitative measurements of [ 18 F]FHBG accumulation in the spleen and LNs of treated mice. These measurements correlated well with the numbers of sr39tk+ melanoma-specific T cells present at these sites determined ex vivo using flow cytometry. We observed that the lower limit of detection, defined as the lowest number of sr39tk+ T cells detected by micro-PET, was dependent on the anatomical location of these cells. In the spleen, the lower limit of detection was ;7 3 10 5 sr39tk+ T cells or in terms of accumulated radioactivity, ;55 nCi of [ 18 F]FHBG. To enable detection by micro-PET, at least ;10% of the total number of cells in the spleen had to express the sr39tk reporter. In contrast, the limit of detection in LNs was 1 3 10 4 sr39tk+ cells, corresponding to ;2-5 nCi of [ 18 F]FHBG, or a frequency of at least ;3% of the total number of cells. The apparent discrepancy between sensitivity parameters in spleen and LNs could be explained by the different architecture of these secondary lymphoid organs. Unlike LNs that consist mainly of lymphocytes, spleens contain a red pulp compartment populated by macrophages and erythrocytes and few lymphocytes. Our data indicate a density of white blood cells in the spleen of ;0.8 3 10
5 mm À3 compared with ;3 3 10 5 mm À3 in a LN. When clinical PET scanners are used to image the heart, brain or tumors, signals from tissues of interest are typically 1.5-to 10-fold above background levels. Our data are within this dynamic range. For example, although PET signal from the brain striatum is typically ;3-fold over background levels in healthy individuals, the precision of PET allows clinicians to monitor the loss of dopaminergic neurons in Parkinson patients (43) .
While our results indicate that PET reporter gene imaging has sufficient sensitivity to enable repeated and non-invasive monitoring of adoptive immunotherapy in a clinically relevant animal model, further improvements might be necessary to fully achieve the potential of this approach. The limit of detection of small animal PET scanners is related to both their sensitivity as well as their intrinsic noise characteristics (44) . While our studies used the micro-PET Focus 220 system (3.5% sensitivity), new instruments such as the Inveon micro-PET (Siemens) are expected to have three times larger peak sensitivity (;10%), from purely geometrical considerations. Furthermore, methods to reduce the intrinsic noise that stems from the natural radioactivity background of the tomographs have been developed (45) . Both these factors (increased sensitivity and energy windowing) can be applied simultaneously to acquisitions that are approaching the limit of detection. It is therefore likely that future studies will enable imaging of a much lower number of cells than those shown here. It is important to note that the lower limit of detection is essentially the same throughout the mouse body (surface or deep), in contrast to bioluminescence or other optical imaging modalities. Similar improvements to enhance sensitivity and resolution are also being performed on clinical PET scanners.
PET imaging biomarkers to evaluate adoptive immunotherapies
A critical finding of our work was that no reproducible patterns of [ 18 F]FHBG accumulation in different LNs across different time points and animals could be observed. While this finding likely reflects the inherent individual variability of T-cell responses and the need for longitudinal immune monitoring studies at a whole-body level, it also raises the question of how PET reporter gene imaging can assist the development of predictive biomarkers. Furthermore, our data emphasize the utility of using reporter gene imaging to noninvasively follow and further understand the variability of distribution and expansion of adoptively transferred T cells in lymphoid organs of patients. Concerning the B16 melanoma model, we observed that the most informative scans were those performed at early time points following AT. Thus, mice showing at least 2-fold increase of [ 18 F]FHBG retention in the spleen and LNs rejected the B16 tumors, whereas the lack of PET probe accumulation at these sites correlated with tumor progression. Importantly, while [ 18 F]FHBG micro-PET scans at later time points (up to 3 weeks) still showed a similar correlation, the treatment efficacy was easily assessed after day 5 by simply measuring the tumor volumes using calipers or CT imaging. Future studies are required to determine whether our findings regarding the optimal schedule of PET reporter gene imaging for defining predictive biomarkers can be generalized to other models of adoptive immunotherapy.
In conclusion, PET reporter gene imaging of AT of melanoma-specific T cells can be used to study the in vivo dynamics of AT of tumor antigen-specific T cells and to define non-invasive predictive biomarkers of treatment efficacy. This technique is amenable to clinical translation and could be incorporated in the next generation of clinical trials to evaluate novel immunotherapy approaches in melanoma and potentially other malignancies.
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